Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose crossover bioequivalence study of methylprednisolone 4 mg tablets under fasting conditions in healthy Chinese subjects
CTR20223196Phase 4Completed
- Sponsor
- Puyang Huiyuan Pharmaceutical
- Start
- Dec 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of methylprednisolone in rheumatism, collagenosis, Not applicable (entry is a general category, not a specific disease), allergy, well-being, sponsored by Puyang Huiyuan Pharmaceutical. Started Dec 2022; status: completed.
02
Drugs
methylprednisolone
03
Conditions
rheumatismcollagenosisNot applicable (entry is a general category, not a specific disease)allergywell-being
Beyond the preview
Go deeper on CTR20223196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223196.